US Aspart Filing Kicks Off Amphastar’s Insulin Ambitions

Could Amphastar Be In Line For The First US FDA Approval For A Novolog Biosimilar?

 
• By Dave Wallace

Amphastar says a “milestone” submission of a US filing for insulin aspart underlines its ambitions in the diabetes segment. But could the firm get the first US biosimilar approval?

Sprinters on starting blocks, race beginning
Who will be first off the blocks with insulin aspart? • Source: Shutterstock

More from Biosimilars

More from Products